GW Pharmaceuticals has chosen the perfect moment to file its cannabis-derived therapy, Epidiolex, with U.S. regulators.
The New England Journal of Medicine just published results from a Phase III study showing that GW’s Epidiolex (derived from cannabidiol) significantly reduced monthly convulsive seizures, especially in children with Dravet syndrome, one of the most difficult types of epilepsy to treat. Children can have dozens, even hundreds, of seizures per month.
GW Pharmaceuticals first reported in March 2016 that CBD-derived Epidiolex cut monthly convulsive seizures by 39 percent in children with Dravet syndrome, but full results of the 120-patient study were only published last week.
The findings stem from a double-blind, placebo-controlled study—the most scientifically rigorous type of investigation possible.
“This study clearly establishes cannabidiol as an effective anti-seizure drug for this disorder and this age group,” said principal investigator and lead author of the study, Dr. Orrin Devinsky, director of the Comprehensive Epilepsy Center at New York University Langone Medical Center.
“It certainly deserves to be studied in other types of epilepsy,” he added.
The journal article also showed that five percent of patients stopped having seizures altogether and 43 percent saw their seizures cut by half.
The treatment, which is given as a syrup, is a purified form of cannabidiol (CBD) and contains less than 0.1 percent of tetrahydrocannabinol (THC).
GW is seeking regulatory approval to sell Epidiolex as a treatment for both Dravet and Lennox-Gastaut syndrome, another severe form of epilepsy.
Stephen Wright, GW’s chief medical officer, said the company would submit its application to the Food and Drug Administration by mid-year, with a filing in Europe following a little later in 2017.
An editorial in the New England Journal of Medicine said the clinical trial represented “the beginning of solid evidence for the use of cannibinoids in epilepsy,” after an era of anecdote and emotional debates.
“These results suggest that Epidiolex can provide clinically meaningful benefits, and I look forward to the prospect of an appropriately standardized and tested pharmaceutical formulation of cannabidiol available as a treatment option for these patients,” said Devinsky.
New Bill Would Allow Medical Marijuana in New Mexico Schools
DC Lawmaker Aims to Get Green Light for Recreational Cannabis Sales
Wisconsin Governor Announces He Will Make “First Step” Toward Legalizing Cannabis
The Cannabis Lobby Is Upping Its Presence In Washington DC
Health6 days ago
Medical Marijuana Recalled From Two Michigan Dispensaries Due to Failed Lab Tests
People6 days ago
Antonio Bascaro: Father. War Hero. Longest Living Pot Prisoner
Legalization7 days ago
Rep. Earl Blumenauer Introduces Bill to Regulate Cannabis Like Alcohol
Medical Marijuana6 days ago
NJ Doctor Suspended for Recommending Medical Marijuana to Thousands of Patients
News3 days ago
Man Leaves Two Pounds of Pot in Uber, is Arrested Trying to Retrieve It
Sponsored6 days ago
CBD vs Kratom: Which Is Best For You?
News2 days ago
Cop Caught with Child Porn Serves 90 Days in Jail; Man Selling Weed Gets 5 Year Sentence
Medical Marijuana7 days ago
Tennessee Lawmakers to Introduce New, Comprehensive Medical Marijuana Bill